Monte Rosa Therapeutics Income Statement (2023-2025) | GLUE

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 1.06M4.70M9.22M60.65M84.93M23.19M12.77M
Operating items
Research & Development 26.75M29.08M28.31M27.14M27.03M28.05M27.62M38.87M32.19M30.65M36.68M
Selling, General & Administrative 7.50M8.14M8.66M7.73M8.98M9.28M8.13M8.78M8.70M8.10M9.06M
Restructuring Costs 6.81M7.62M7.46M7.75M8.23M7.85M8.57M
Other Operating Expenses -6.81M-7.62M-7.46M-7.75M0.06M-7.85M-8.57M
Operating Expenses 34.26M37.22M36.97M34.86M36.01M37.34M35.74M47.64M40.89M38.75M45.74M
Operating Income -34.26M-37.22M-36.97M-34.86M-34.95M-32.64M-26.53M13.00M44.04M-15.55M-32.98M
EBIT -34.26M-37.22M-36.97M-34.86M-34.95M-32.64M-26.53M13.00M44.04M-15.55M-32.98M
Non-operating items
Non Operating Investment Income -0.13M
Interest & Investment Income 2.44M2.30M2.23M2.37M2.44M2.64M2.89M2.60M3.44M3.07M2.75M
Other Non Operating Income -0.09M-0.09M0.03M-0.78M0.62M-0.05M-0.15M0.00M0.17M1.39M-0.03M
Non Operating Income 2.22M2.23M2.25M1.59M3.06M2.58M2.74M2.60M3.67M4.46M2.72M
Net income details
EBT -32.04M-34.99M-34.71M-33.27M-31.89M-30.06M-23.79M15.60M47.71M-11.10M-30.26M
Tax Provisions 0.19M0.17M-0.02M0.10M0.25M0.07M2.19M0.82M1.20M-3.18M
Profit After Tax -32.04M-35.18M-34.88M-33.30M-31.97M-30.31M-23.86M13.44M46.88M-12.29M-27.08M
Income from Continuing Operations -32.04M-35.18M-34.88M-33.25M-31.98M-30.31M-23.86M13.41M46.88M-12.29M-27.08M
Consolidated Net Income -32.04M-35.18M-34.88M-33.25M-31.98M-30.31M-23.86M13.41M46.88M-12.29M-27.08M
Income towards Parent Company -32.04M-35.18M-34.88M-33.25M-31.98M-30.31M-23.86M13.41M46.88M-12.29M-27.08M
Net Income towards Common Stockholders -32.04M-35.18M-34.88M-33.25M-31.98M-30.31M-23.86M13.41M46.88M-12.29M-27.08M
Additional items
EPS (Basic) -0.65-0.71-0.70-0.57-0.53-0.43-0.290.230.57-0.15-0.33
EPS (Weighted Average and Diluted) -0.65-0.71-0.70-0.57-0.53-0.43-0.290.230.57-0.15-0.33
Shares Outstanding (Weighted Average) 49.36M49.38M49.66M50.08M50.15M50.51M61.37M61.44M61.51M61.51M61.76M
Shares Outstanding (Diluted Average) 49.35M49.43M49.81M51.40M60.16M71.23M82.01M73.91M82.96M82.89M82.94M
EBITDA -31.68M-35.42M-34.70M-34.52M-31.94M-30.29M-23.51M12.40M46.91M-12.34M-26.95M
Tax Rate 0.07%14.06%1.72%10.50%